Parenteral Drugs (India)
Parenteral Drugs (India) Performance
Day Range
- Low 2.7
- High 2.9
52 Week Range
- Low 2.7
- High 4.8
- Open Price2.7
- Previous Close2.85
- Volume1063
Start SIP in Parenteral Drugs (India)
Start SIPParenteral Drugs (India) Investment Rating
-
Master Rating:
-
Parenteral Drugs India has an operating revenue of Rs. 8.50 Cr. on a trailing 12-month basis. An annual revenue de-growth of -30% needs improvement, Pre-tax margin of -1284% needs improvement, NULL It is currently FORMING a base in its weekly chart and is trading around 39% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2022 |
|---|---|
| Oper Rev Qtr Cr | 2 |
| Operating Expenses Qtr Cr | 8 |
| Operating Profit Qtr Cr | -6 |
| Depreciation Qtr Cr | 27 |
| Interest Qtr Cr | 0 |
| Tax Qtr Cr | -5 |
| Net Profit Qtr Cr | 24 |
Parenteral Drugs (India) Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹3.24
- 50 Day
- ₹3.47
- 100 Day
- ₹3.54
- 200 Day
- ₹3.72
- 20 Day
- ₹3.27
- 50 Day
- ₹3.59
- 100 Day
- ₹3.6
- 200 Day
- ₹3.48
Parenteral Drugs (India) Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹2.97 |
| Second Resistance | ₹3.04 |
| Third Resistance | ₹3.17 |
| RSI | 36.04 |
| MFI | 3.73 |
| MACD Single Line | -0.2 |
| MACD | -0.22 |
| Support | |
|---|---|
| First Resistance | ₹2.77 |
| Second Resistance | ₹2.64 |
| Third Resistance | ₹2.57 |
Parenteral Drugs (India) Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | |||
| Week | |||
| 1 Month | |||
| 6 Month | 448 | 44,843 | 100 |
Parenteral Drugs (India) Result Highlights
Parenteral Drugs (India) Synopsis
NSE-Medical-Diversified
Parenteral Drugs is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 12.17 Cr. and Equity Capital is Rs. 29.82 Cr. for the Year ended 31/03/2021. Parenteral Drugs (India) Ltd. is a Public Limited Listed company incorporated on 13/12/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC126481 and registration number is 126481.| Market Cap | 9 |
| Sales | 8 |
| Shares in Float | 0.81 |
| No of funds | |
| Yield |
| Book Value | -0.02 |
| U/D Vol ratio | 0.2 |
| LTDebt / Equity | |
| Alpha | -0.35 |
| Beta | 0.53 |
Parenteral Drugs (India)
| Owner Name |
|---|
Parenteral Drugs (India) Management
| Name | Designation |
|---|---|
| Mr. Manohar Lal Gupta | Chairman & Non-Exe.Director |
| Mr. Vinod Kumar Gupta | Managing Director & CFO |
| Mr. Govind Das Garg | Whole Time Director |
| Mr. Dharam Pal Khanna | Ind. Non-Executive Director |
| Mr. Dilip Kumar Sinha | Ind. Non-Executive Director |
| Mrs. Deepali Garhewal | Ind. Non-Executive Director |
| Mr. Manish Verma | Ind. Non-Executive Director |
| Mr. Anil Mittal | Non Executive Director |
Parenteral Drugs (India) Forecast
Price Estimates
Parenteral Drugs (India) Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-05-30 | Audited Results & Others | Inter alia, to consider : The shifting of registered office of the Company within local limits of the city. |
| 2022-02-14 | Quarterly Results | |
| 2022-02-02 | Others | inter alia, To consider appointment of Independent Director and to consider sale, lease or disposal of the whole or substantially the whole of the undertaking of the Company. |
| 2021-11-12 | Quarterly Results | |
| 2021-08-10 | Quarterly Results |
- Company Name
- CMP
- Chg(%)
- Bajaj Finance
- 7820
- 4.7
- Tata Consumer
- 901
- 2.6
- Bajaj Finserv
- 1577
- 2.2
- Apollo Hospitals
- 5097
- 2.2
- Coal India
- 288
- 1.7
- Company Name
- CMP
- Chg(%)
- Hindalco Inds.
- 469
- -2.0
- SBI Life Insuran
- 1294
- -1.9
- Hero Motocorp
- 2975
- -1.6
- Infosys
- 1474
- -1.5
- Dr Reddys Labs
- 5439
- -1.4
Parenteral Drugs (India) FAQs
What is Share Price of Parenteral Drugs (India) ?
Parenteral Drugs (India) share price is ₹2 As on 25 September, 2023 | 21:12
What is the Market Cap of Parenteral Drugs (India) ?
The Market Cap of Parenteral Drugs (India) is ₹8.6 Cr As on 25 September, 2023 | 21:12
What is the P/E ratio of Parenteral Drugs (India) ?
The P/E ratio of Parenteral Drugs (India) is -0.1 As on 25 September, 2023 | 21:12
What is the PB ratio of Parenteral Drugs (India) ?
The PB ratio of Parenteral Drugs (India) is -0 As on 25 September, 2023 | 21:12